INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro(TM) to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference October 17, 2023